OM
ACRS icon

Opaleye Management’s Aclaris Therapeutics ACRS Stock Holding History

Opaleye Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-18,000
Closed -$341K – 50
2016
Q1 		$341K Buy
+18,000
New +$344K 0.21% 50

Other funds holding ACRS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Opaleye Management's ACRS Position: Q2 2016 in Review

Opaleye Management sold out of Aclaris Therapeutics (ACRS) in Q2 2016, closing a stake of 18,000 shares — an estimated $341K sold.

Opaleye Management first reported a position in ACRS in Q1 2016 and held it in 1 quarter. The position peaked at $341K in Q1 2016. 46 funds tracked by Wall St. Rank hold ACRS as of Q2 2016.

  • Opaleye Management reported no remaining Aclaris Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Opaleye Management sold 18,000 Aclaris Therapeutics shares in Q2 2016, an estimated $341K.
  • Opaleye Management first reported a position in Aclaris Therapeutics in Q1 2016 and held it in 1 quarter.
  • Opaleye Management's Aclaris Therapeutics position peaked at $341K in Q1 2016.
  • 46 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2016.

Based on Opaleye Management's 13F filing for Q2 2016, filed 12 Aug 2016.